このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Societal CDMO 過去の業績

過去基準チェック /06

Societal CDMOの収益は年間平均-31.7%の割合で減少していますが、 Pharmaceuticals業界の収益は年間減少しています。収益は年間0.4% 0.8%割合で増加しています。

主要情報

-31.7%

収益成長率

-17.4%

EPS成長率

Pharmaceuticals 業界の成長	6.0%
収益成長率	0.8%
株主資本利益率	-22.6%
ネット・マージン	-14.0%
前回の決算情報	31 Dec 2023

Recent updates

Societal CDMO, Inc.'s (NASDAQ:SCTL) Price Is Right But Growth Is Lacking After Shares Rocket 38%

Feb 10

Is There An Opportunity With Societal CDMO, Inc.'s (NASDAQ:SCTL) 46% Undervaluation?

Feb 02

These 4 Measures Indicate That Societal CDMO (NASDAQ:SCTL) Is Using Debt Extensively

Apr 29

Is Recro Pharma (NASDAQ:REPH) A Risky Investment?

Jan 06

Recro Pharma jumps 15% on Q1 result estimates beat

May 07

Would Shareholders Who Purchased Recro Pharma's (NASDAQ:REPH) Stock Year Be Happy With The Share price Today?

Feb 15

収支内訳

Societal CDMO の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:SCTL 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Dec 23	95	-13	21	0
30 Sep 23	91	-22	21	0
30 Jun 23	89	-20	21	0
31 Mar 23	91	-20	21	0
31 Dec 22	90	-20	22	0
30 Sep 22	88	-13	20	0
30 Jun 22	85	-13	20	0
31 Mar 22	80	-9	18	0
31 Dec 21	75	-11	17	0
30 Sep 21	63	-21	17	0
30 Jun 21	64	-19	17	0
31 Mar 21	62	-27	17	0
31 Dec 20	66	-28	18	0
30 Sep 20	74	-21	18	0
30 Jun 20	80	-14	18	0
31 Mar 20	96	-3	19	0
31 Dec 19	99	5	20	0
30 Sep 19	99	35	1	0
30 Jun 19	92	17	4	0
31 Mar 19	83	0	11	0
31 Dec 18	77	-13	14	0
30 Sep 18	79	-63	38	0
30 Jun 18	77	-58	38	0
31 Mar 18	73	-54	31	0
31 Dec 17	72	-7	14	0
30 Sep 17	70	-36	20	0
30 Jun 17	70	-33	18	0
31 Mar 17	70	-32	14	0
31 Dec 16	69	-30	13	0
30 Sep 16	69	-9	14	0
30 Jun 16	68	-6	13	0
31 Mar 16	70	1	13	0
31 Dec 15	52	3	13	0
30 Sep 15	35	-11	10	0
30 Jun 15	19	-14	7	0
31 Mar 15	0	-15	6	0
31 Dec 14	0	-17	4	0
30 Sep 14	0	-14	3	0
30 Jun 14	0	-10	2	0
31 Mar 14	0	-8	1	0
31 Dec 13	0	-2	1	1
30 Sep 13	0	-2	1	1

質の高い収益: SCTLは現在利益が出ていません。

利益率の向上: SCTLは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: SCTLは利益が出ておらず、過去 5 年間で損失は年間31.7%の割合で増加しています。

成長の加速: SCTLの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: SCTLは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 19.9% ) と比較することは困難です。

株主資本利益率

高いROE: SCTLは現在利益が出ていないため、自己資本利益率 ( -22.63% ) はマイナスです。

Societal CDMO 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Societal CDMO, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Societal CDMO, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Societal CDMO, Inc. to Report Q1, 2023 Results on May 10, 2023

Recent updates

Societal CDMO, Inc. Files Form 15

Societal CDMO, Inc.(NasdaqCM:SCTL) dropped from NASDAQ Composite Index

Societal CDMO's Common Stock to be Delisted from the Nasdaq Capital Market as a Result of the Merger with CoreRx

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CoreRx, Inc. entered into a definitive agreement to acquire Societal CDMO, Inc. (NasdaqCM:SCTL) from First Light Asset Management, LLC and Others for approximately $120 million.

New major risk - Share price stability

Now 29% overvalued after recent price rise

Societal CDMO, Inc.'s (NASDAQ:SCTL) Price Is Right But Growth Is Lacking After Shares Rocket 38%

Is There An Opportunity With Societal CDMO, Inc.'s (NASDAQ:SCTL) 46% Undervaluation?

Is Societal CDMO (NASDAQ:SCTL) Weighed On By Its Debt Load?

Price target decreased by 14% to US$1.86

High number of new directors

Nasdaq Grants Societal CDMO an Additional 180 Calendar Days to Regain Compliance with Minimum Bid Price Requirement

Societal CDMO, Inc. Resets Earnings Guidance for the Year 2023

Societal CDMO, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Societal CDMO, Inc. Reduces its Workforce by 26 Positions Across All Aspects of the Business

High number of new directors

Price target decreased by 18% to US$2.30

Societal CDMO, Inc. has completed a Follow-on Equity Offering.

Societal Cdmo Announces Appointment of Matt Arens to Board of Directors

Consensus EPS estimates fall by 18%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS misses analyst expectations

Societal CDMO, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Share price stability

Does Societal CDMO (NASDAQ:SCTL) Have A Healthy Balance Sheet?

Societal CDMO Receives Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Societal CDMO, Inc. Reaffirms 2023 Financial Guidance

Societal CDMO, Inc. to Report Q1, 2023 Results on May 10, 2023

Forecast to breakeven in 2025

Price target decreased by 13% to US$3.64

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 19% to US$5.00

Consensus EPS estimates fall by 16%

Societal CDMO, Inc. has completed a Follow-on Equity Offering in the amount of $30.625911 million.

Societal CDMO, Inc. has completed a Follow-on Equity Offering in the amount of $30.625911 million.

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Societal CDMO, Inc. Provides Earnings Guidance for the Full Year 2022

Societal CDMO, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Societal CDMO signs two CDMO service agreements

Societal CDMO, Inc. Appoints Elena Cant as Board of Directors

Societal stock soars 20% on signing 2 manufacturing contracts

Societal CDMO estimates to receive up to $50M on real estates' sales

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Societal CDMO, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2022

Societal CDMO, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Societal CDMO, Lannett amend license and supply deal

Railroad Ranch Capital Engages in Discussions with Societal CDMO

Societal Cdmo Unveils 20/80 Second Source Technical Transfer Service Model, Offering Cost and Time Savings for Pharmaceutical Manufacturing

Consensus forecasts updated

Societal CDMO, Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Societal CDMO, Inc. to Report Q1, 2022 Results on May 11, 2022

These 4 Measures Indicate That Societal CDMO (NASDAQ:SCTL) Is Using Debt Extensively

Price target decreased to US$5.00

Societal CDMO, Inc., Annual General Meeting, May 18, 2022

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Recro Pharma, Inc. Provides Earnings Guidance for the Year 2022

Recro Pharma, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Is Recro Pharma (NASDAQ:REPH) A Risky Investment?

Third quarter 2021 earnings released: US$0.068 loss per share (vs US$0.09 loss in 3Q 2020)

Consensus forecasts updated

Consensus forecasts updated

Recro Pharma, Inc. (NasdaqCM:REPH) acquired IRISYS, LLC from EPS Americas, Corp., IriSys, Inc. and Continent Pharmaceuticals U.S., Inc. for $51.7 million.

Second quarter 2021 earnings released: EPS US$0.032 (vs US$0.26 loss in 2Q 2020)

Recro Pharma, Inc.(NasdaqCM:REPH) dropped from Russell 3000E Growth Index

Recro Pharma, Inc. Expands Capabilities for Growing Clinical Trial Services Offerings

Recro Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $29.999999 million.

過去基準チェック /06